Acute treatments

Brian G Weinshenker, Nima Mowzoon

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Most patients with multiple sclerosis (MS) experience relapses characterized by acute or subacute neurological dysfunction lasting days to several weeks followed by a remission with partial or complete resolution of neurological dysfunction. Attacks may occur as part of diverse demyelinating syndromes: clinically isolated syndromes [e.g., isolated optic neuritis (ON), myelitis, or brainstem syndromes], relapsingremitting MS (RRMS) or secondary progressive MS, or one of the atypical demyelinating disease variants (Marburg variant, tumefactive MS, severe monophasic disorders such as complete transverse myelitis and neuromyelitis optica). The goals of acute treatment are reversal of neurological disability sustained from an attack, arrest of rapidly deteriorating neurological dysfunction, and restoration of function. This may be distinguished from the goals of long-term therapies, such as interferon beta and glatiramer acetate, which are not known to alter the course of an individual attack and its sequelae, but rather to reduce the probability of subsequent clinical and subclinical attacks.

Original languageEnglish (US)
Title of host publicationHandbook of Multiple Sclerosis, Fourth Edition
PublisherCRC Press
Pages301-316
Number of pages16
ISBN (Electronic)9781420018714
ISBN (Print)9781574448276
StatePublished - Jan 1 2006
Externally publishedYes

Fingerprint

Multiple Sclerosis
Transverse Myelitis
Neuromyelitis Optica
Chronic Progressive Multiple Sclerosis
Myelitis
Optic Neuritis
Interferon-beta
Demyelinating Diseases
Brain Stem
Therapeutics
Recurrence
Glatiramer Acetate

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)

Cite this

Weinshenker, B. G., & Mowzoon, N. (2006). Acute treatments. In Handbook of Multiple Sclerosis, Fourth Edition (pp. 301-316). CRC Press.

Acute treatments. / Weinshenker, Brian G; Mowzoon, Nima.

Handbook of Multiple Sclerosis, Fourth Edition. CRC Press, 2006. p. 301-316.

Research output: Chapter in Book/Report/Conference proceedingChapter

Weinshenker, BG & Mowzoon, N 2006, Acute treatments. in Handbook of Multiple Sclerosis, Fourth Edition. CRC Press, pp. 301-316.
Weinshenker BG, Mowzoon N. Acute treatments. In Handbook of Multiple Sclerosis, Fourth Edition. CRC Press. 2006. p. 301-316
Weinshenker, Brian G ; Mowzoon, Nima. / Acute treatments. Handbook of Multiple Sclerosis, Fourth Edition. CRC Press, 2006. pp. 301-316
@inbook{cb121aa3dd624c87a7e4f304e6a81667,
title = "Acute treatments",
abstract = "Most patients with multiple sclerosis (MS) experience relapses characterized by acute or subacute neurological dysfunction lasting days to several weeks followed by a remission with partial or complete resolution of neurological dysfunction. Attacks may occur as part of diverse demyelinating syndromes: clinically isolated syndromes [e.g., isolated optic neuritis (ON), myelitis, or brainstem syndromes], relapsingremitting MS (RRMS) or secondary progressive MS, or one of the atypical demyelinating disease variants (Marburg variant, tumefactive MS, severe monophasic disorders such as complete transverse myelitis and neuromyelitis optica). The goals of acute treatment are reversal of neurological disability sustained from an attack, arrest of rapidly deteriorating neurological dysfunction, and restoration of function. This may be distinguished from the goals of long-term therapies, such as interferon beta and glatiramer acetate, which are not known to alter the course of an individual attack and its sequelae, but rather to reduce the probability of subsequent clinical and subclinical attacks.",
author = "Weinshenker, {Brian G} and Nima Mowzoon",
year = "2006",
month = "1",
day = "1",
language = "English (US)",
isbn = "9781574448276",
pages = "301--316",
booktitle = "Handbook of Multiple Sclerosis, Fourth Edition",
publisher = "CRC Press",

}

TY - CHAP

T1 - Acute treatments

AU - Weinshenker, Brian G

AU - Mowzoon, Nima

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Most patients with multiple sclerosis (MS) experience relapses characterized by acute or subacute neurological dysfunction lasting days to several weeks followed by a remission with partial or complete resolution of neurological dysfunction. Attacks may occur as part of diverse demyelinating syndromes: clinically isolated syndromes [e.g., isolated optic neuritis (ON), myelitis, or brainstem syndromes], relapsingremitting MS (RRMS) or secondary progressive MS, or one of the atypical demyelinating disease variants (Marburg variant, tumefactive MS, severe monophasic disorders such as complete transverse myelitis and neuromyelitis optica). The goals of acute treatment are reversal of neurological disability sustained from an attack, arrest of rapidly deteriorating neurological dysfunction, and restoration of function. This may be distinguished from the goals of long-term therapies, such as interferon beta and glatiramer acetate, which are not known to alter the course of an individual attack and its sequelae, but rather to reduce the probability of subsequent clinical and subclinical attacks.

AB - Most patients with multiple sclerosis (MS) experience relapses characterized by acute or subacute neurological dysfunction lasting days to several weeks followed by a remission with partial or complete resolution of neurological dysfunction. Attacks may occur as part of diverse demyelinating syndromes: clinically isolated syndromes [e.g., isolated optic neuritis (ON), myelitis, or brainstem syndromes], relapsingremitting MS (RRMS) or secondary progressive MS, or one of the atypical demyelinating disease variants (Marburg variant, tumefactive MS, severe monophasic disorders such as complete transverse myelitis and neuromyelitis optica). The goals of acute treatment are reversal of neurological disability sustained from an attack, arrest of rapidly deteriorating neurological dysfunction, and restoration of function. This may be distinguished from the goals of long-term therapies, such as interferon beta and glatiramer acetate, which are not known to alter the course of an individual attack and its sequelae, but rather to reduce the probability of subsequent clinical and subclinical attacks.

UR - http://www.scopus.com/inward/record.url?scp=85024404868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85024404868&partnerID=8YFLogxK

M3 - Chapter

SN - 9781574448276

SP - 301

EP - 316

BT - Handbook of Multiple Sclerosis, Fourth Edition

PB - CRC Press

ER -